Clinical trials: Clinical High-risk Syndrome of Psychosis
Clinical High Risk Syndrome of Psychosis
Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)
This is a randomized, double-blind, placebo-controlled, multi-centre trial. A total of 300 CHR subjects will be identified in the course of face-to-face interviews using the Structured Interview for Prodromal Syndromes.
- Trial name
- NCT03932136
- Testing
- Sulforaphane
- Where
- 9 sites in China
- Volunteers
- 300 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Clinical High-risk Syndrome of Psychosis
RTMS for CHR Based on Personalized Targets Using Magnetoencephalography
This study is an before-after study in the same subject, which enrolled 26 individuals with high-risk psychiatric syndrome (CHR). The target of subjects intervention relies on the results of magnetoencephalography localization.
- Trial name
- NCT06802952
- Testing
- rTMS
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Shanghai Mental Health Center
Clinical High Risk Syndrome for Psychosis
PRIME vs Usual Care for Clinical High Risk
The purpose of this study is to determine whether specialty care is superior to usual care in the treatment of patients at clinical high risk for psychosis.
- Trial name
- NCT02960451
- Testing
- PRIME care, Usual care
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Yale University